EP 101 - EpiThany

Drug Profile

EP 101 - EpiThany

Alternative Names: EP-101 - EpiThany

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EpiThany; University of Washington
  • Class Antigens; Vaccines
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 10 May 2017 EpiThany, Merck and Pfizer agree to co-develop EP 101, in combination with avelumab for Breast cancer
  • 10 May 2017 EpiThany plans a phase II trial for Breast Cancer (Combination therapy, Neoadjuvant therapy)
  • 05 Oct 2016 Phase-I clinical trials in Breast cancer in USA (Parenteral) (EpiThany pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top